ApprovalTrail

Approval · Notice of Compliance 26259 · 2021

PROZAC: Notice of Compliance 26259

Issued July 14, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
26259
Date
July 14, 2021
Company
Eli Lilly Canada IncToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Updates to the Product Monograph

Products in this notice

BrandDINStatus today
PROZACNot yet assigned—

Medicinal ingredients